Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
IRF3 promotes adipose inflammation and insulin resistance and represses browning
Manju Kumari, … , Rasheed Ahmad, Evan D. Rosen
Manju Kumari, … , Rasheed Ahmad, Evan D. Rosen
Published July 11, 2016
Citation Information: J Clin Invest. 2016;126(8):2839-2854. https://doi.org/10.1172/JCI86080.
View: Text | PDF
Research Article Metabolism

IRF3 promotes adipose inflammation and insulin resistance and represses browning

  • Text
  • PDF
Abstract

The chronic inflammatory state that accompanies obesity is a major contributor to insulin resistance and other dysfunctional adaptations in adipose tissue. Cellular and secreted factors promote the inflammatory milieu of obesity, but the transcriptional pathways that drive these processes are not well described. Although the canonical inflammatory transcription factor NF-κB is considered to be the major driver of adipocyte inflammation, members of the interferon regulatory factor (IRF) family may also play a role in this process. Here, we determined that IRF3 expression is upregulated in the adipocytes of obese mice and humans. Signaling through TLR3 and TLR4, which lie upstream of IRF3, induced insulin resistance in murine adipocytes, while IRF3 knockdown prevented insulin resistance. Furthermore, improved insulin sensitivity in IRF3-deficient mice was associated with reductions in intra-adipose and systemic inflammation in the high fat–fed state, enhanced browning of subcutaneous fat, and increased adipose expression of GLUT4. Taken together, the data indicate that IRF3 is a major transcriptional regulator of adipose inflammation and is involved in maintaining systemic glucose and energy homeostasis.

Authors

Manju Kumari, Xun Wang, Louise Lantier, Anna Lyubetskaya, Jun Eguchi, Sona Kang, Danielle Tenen, Hyun Cheol Roh, Xingxing Kong, Lawrence Kazak, Rasheed Ahmad, Evan D. Rosen

×

Figure 2

IRF3 regulates insulin sensitivity in adipocytes in a cell-autonomous fashion.

Options: View larger image (or click on image) Download as PowerPoint
IRF3 regulates insulin sensitivity in adipocytes in a cell-autonomous fa...
(A) Basal and insulin-stimulated glucose uptake in 3T3-L1 adipocytes after treatment with varying doses of LPS for 6 days. (B) Western blot showing phosphorylation of murine IRF3 (Ser388) in 3T3-L1 adipocytes after 6 days of LPS (700 ng/ml) treatment. (C) Basal and insulin-stimulated glucose uptake in 3T3-L1 adipocytes transduced with lentivirus expressing shRNA against Irf3 or shLuc control hairpin in the absence or presence of LPS treatment (700 ng/ml). (D) Basal and insulin-stimulated glucose uptake in 3T3-L1 adipocytes after treatment with varying doses of poly I:C. (E) Western blot showing phosphorylation of IRF3 in 3T3-L1 adipocytes after 24 hours of poly I:C (5 μg/ml) treatment. (F) Basal and insulin-stimulated glucose uptake in 3T3-L1 adipocytes transduced with lentivirus expressing shRNA against Irf3 or shLuc control hairpin in the absence or presence of poly I:C treatment (5 μg/ml). (G) Basal and insulin-stimulated glucose uptake in 3T3-L1 adipocytes expressing WT IRF3 or IRF3-2D mutant. Data in all panels expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts